We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
GEHC and Mayo Clinic Launch GEMINI-RT to Aid Personalized Cancer Care
Read MoreHide Full Article
Key Takeaways
GEHC and Mayo Clinic launched GEMINI-RT to modernize personalized radiation therapy across the cancer pathway.
The initiative targets automation, predictive oncology, multi-modal therapies and connected patient care.
GEHC expects the collaboration to enhance workflows and deepen its oncology technology pipeline.
GE HealthCare (GEHC - Free Report) and Mayo Clinic have recently launched GEMINI-RT, a new research initiative aimed at reshaping personalized radiation therapy by combining advanced imaging, AI and patient monitoring across the full cancer care pathway. The collaboration builds on their long-standing research partnership and is focused on developing smarter, data-driven tools that can improve precision from diagnosis through follow-up.
Per management, GEMINI-RT is likely to accelerate innovation in key areas such as automation, predictive oncology, multi-modal treatment strategies and connected patient care. By pairing Mayo Clinic’s deep clinical expertise with GEHC’s engineering and AI capabilities, the initiative is expected to enhance clinical workflows, support better outcomes and reduce burnout for care teams.
Likely Trend of GEHC Stock Following the News
Following the announcement, the company's shares traded flat at yesterday’s closing. In the year-to-date period, shares have gained 6.9% compared with the industry’s 3.4% growth. The S&P 500 has gained 18.9% in the same time frame.
In the long run, GEMINI-RT is likely to strengthen GEHC’s competitive position in oncology by anchoring its technology directly into next-generation clinical workflows developed with one of the world’s leading cancer centers. The collaboration deepens GEHC’s pipeline in AI, imaging and radiation therapy planning, expands its role in multi-modal oncology care, and accelerates innovation that can translate into future commercial products. By shaping emerging standards in personalized radiation therapy and connected care, GEHC stands to grow its influence, strengthen customer loyalty and capture a larger share of a rapidly expanding global cancer-care market.
GEHC currently has a market capitalization of $36.44 billion.
Image Source: Zacks Investment Research
More on the News
GEMINI-RT represents a significant deepening of GE HealthCare’s collaboration with Mayo Clinic, building on their 2023 radiology research alliance and extending it into the core of radiation oncology. The initiative aims to modernize and personalize radiation therapy by integrating imaging, AI, dosimetry and patient-monitoring tools across every stage of care. By partnering directly with Mayo Clinic’s world-class clinical and research teams, GEHC gains access to unique patient insights, real-world workflows and outcomes data that can meaningfully shape product development and accelerate translational innovation.
The collaboration is centered around four strategic areas—automation, predictive oncology, multi-modal therapies and connected care. Automation efforts will focus on reducing repetitive planning tasks with AI-driven tools, while predictive oncology uses clinical data to tailor treatment decisions with greater accuracy.
Multi-modal therapy research will explore ways to combine radiation with emerging targeted treatments, and connected care initiatives aim to extend monitoring beyond the clinic, using sensors and AI to predict side effects earlier and support at-home management. Together, these pillars create a comprehensive framework for improving patient outcomes and easing clinician workload.
For GEHC, the long-term strategic upside is substantial. Working alongside Mayo Clinic provides a powerful validation pathway for next-generation oncology technologies and helps GEHC embed its solutions into future standards of care.
As global cancer incidence continues to rise, the demand for more personalized, efficient and scalable radiation therapy will expand. By co-developing the tools that could define this new model, GEHC is positioned to strengthen its oncology portfolio, deepen customer adoption and capture sustained growth opportunities in one of the fastest-evolving areas of healthcare.
GEHC’s Zacks Rank & Key Picks
Currently, GEHC carries a Zacks Rank #3 (Hold).
Some better-ranked stocks from the broader medical space are Medpace Holdings (MEDP - Free Report) , Intuitive Surgical (ISRG - Free Report) and Boston Scientific (BSX - Free Report) .
Medpace, currently carrying a Zacks Rank #2 (Buy), reported a third-quarter 2025 earnings per share (EPS) of $3.86, which surpassed the Zacks Consensus Estimate by 10.29%. Revenues of $659.9 million beat the Zacks Consensus Estimate by 3.04%. You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
MEDP has an estimated earnings growth rate of 17.1% for 2025 compared with the industry’s 16.6% growth. The company beat earnings estimates in each of the trailing four quarters, the average surprise being 14.28%.
Intuitive Surgical, sporting a Zacks Rank #1 at present, posted a third-quarter 2025 adjusted EPS of $2.40, exceeding the Zacks Consensus Estimate by 20.6%. Revenues of $2.51 billion topped the Zacks Consensus Estimate by 3.9%.
ISRG has an estimated long-term earnings growth rate of 15.7% compared with the industry’s 11.9% growth. The company’s earnings outpaced estimates in each of the trailing four quarters, the average surprise being 16.34%.
Boston Scientific, currently carrying a Zacks Rank #2, reported a third-quarter 2025 adjusted EPS of 75 cents, which surpassed the Zacks Consensus Estimate by 5.6%. Revenues of $5.07 billion outperformed the Zacks Consensus Estimate by 1.9%.
BSX has an estimated long-term earnings growth rate of 16.4% compared with the industry’s 13.5% growth. The company’s earnings beat estimates in each of the trailing four quarters, the average surprise being 7.36%.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
GEHC and Mayo Clinic Launch GEMINI-RT to Aid Personalized Cancer Care
Key Takeaways
GE HealthCare (GEHC - Free Report) and Mayo Clinic have recently launched GEMINI-RT, a new research initiative aimed at reshaping personalized radiation therapy by combining advanced imaging, AI and patient monitoring across the full cancer care pathway. The collaboration builds on their long-standing research partnership and is focused on developing smarter, data-driven tools that can improve precision from diagnosis through follow-up.
Per management, GEMINI-RT is likely to accelerate innovation in key areas such as automation, predictive oncology, multi-modal treatment strategies and connected patient care. By pairing Mayo Clinic’s deep clinical expertise with GEHC’s engineering and AI capabilities, the initiative is expected to enhance clinical workflows, support better outcomes and reduce burnout for care teams.
Likely Trend of GEHC Stock Following the News
Following the announcement, the company's shares traded flat at yesterday’s closing. In the year-to-date period, shares have gained 6.9% compared with the industry’s 3.4% growth. The S&P 500 has gained 18.9% in the same time frame.
In the long run, GEMINI-RT is likely to strengthen GEHC’s competitive position in oncology by anchoring its technology directly into next-generation clinical workflows developed with one of the world’s leading cancer centers. The collaboration deepens GEHC’s pipeline in AI, imaging and radiation therapy planning, expands its role in multi-modal oncology care, and accelerates innovation that can translate into future commercial products. By shaping emerging standards in personalized radiation therapy and connected care, GEHC stands to grow its influence, strengthen customer loyalty and capture a larger share of a rapidly expanding global cancer-care market.
GEHC currently has a market capitalization of $36.44 billion.
Image Source: Zacks Investment Research
More on the News
GEMINI-RT represents a significant deepening of GE HealthCare’s collaboration with Mayo Clinic, building on their 2023 radiology research alliance and extending it into the core of radiation oncology. The initiative aims to modernize and personalize radiation therapy by integrating imaging, AI, dosimetry and patient-monitoring tools across every stage of care. By partnering directly with Mayo Clinic’s world-class clinical and research teams, GEHC gains access to unique patient insights, real-world workflows and outcomes data that can meaningfully shape product development and accelerate translational innovation.
The collaboration is centered around four strategic areas—automation, predictive oncology, multi-modal therapies and connected care. Automation efforts will focus on reducing repetitive planning tasks with AI-driven tools, while predictive oncology uses clinical data to tailor treatment decisions with greater accuracy.
Multi-modal therapy research will explore ways to combine radiation with emerging targeted treatments, and connected care initiatives aim to extend monitoring beyond the clinic, using sensors and AI to predict side effects earlier and support at-home management. Together, these pillars create a comprehensive framework for improving patient outcomes and easing clinician workload.
For GEHC, the long-term strategic upside is substantial. Working alongside Mayo Clinic provides a powerful validation pathway for next-generation oncology technologies and helps GEHC embed its solutions into future standards of care.
As global cancer incidence continues to rise, the demand for more personalized, efficient and scalable radiation therapy will expand. By co-developing the tools that could define this new model, GEHC is positioned to strengthen its oncology portfolio, deepen customer adoption and capture sustained growth opportunities in one of the fastest-evolving areas of healthcare.
GEHC’s Zacks Rank & Key Picks
Currently, GEHC carries a Zacks Rank #3 (Hold).
Some better-ranked stocks from the broader medical space are Medpace Holdings (MEDP - Free Report) , Intuitive Surgical (ISRG - Free Report) and Boston Scientific (BSX - Free Report) .
Medpace, currently carrying a Zacks Rank #2 (Buy), reported a third-quarter 2025 earnings per share (EPS) of $3.86, which surpassed the Zacks Consensus Estimate by 10.29%. Revenues of $659.9 million beat the Zacks Consensus Estimate by 3.04%. You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
MEDP has an estimated earnings growth rate of 17.1% for 2025 compared with the industry’s 16.6% growth. The company beat earnings estimates in each of the trailing four quarters, the average surprise being 14.28%.
Intuitive Surgical, sporting a Zacks Rank #1 at present, posted a third-quarter 2025 adjusted EPS of $2.40, exceeding the Zacks Consensus Estimate by 20.6%. Revenues of $2.51 billion topped the Zacks Consensus Estimate by 3.9%.
ISRG has an estimated long-term earnings growth rate of 15.7% compared with the industry’s 11.9% growth. The company’s earnings outpaced estimates in each of the trailing four quarters, the average surprise being 16.34%.
Boston Scientific, currently carrying a Zacks Rank #2, reported a third-quarter 2025 adjusted EPS of 75 cents, which surpassed the Zacks Consensus Estimate by 5.6%. Revenues of $5.07 billion outperformed the Zacks Consensus Estimate by 1.9%.
BSX has an estimated long-term earnings growth rate of 16.4% compared with the industry’s 13.5% growth. The company’s earnings beat estimates in each of the trailing four quarters, the average surprise being 7.36%.